Development and characterization of HAT-sensitive Ewing tumour cells for immunotherapy

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4489-4496

  Pfeifle, Christian ^a   Reinhardt, Kerstin ^a   Heins, Sigrid ^a   Burdach, Stefan ^b   Staege, Martin S ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cell fusion; Ewing tumours; Gene expression; HAT selection; Immunotherapy

Indexed keywords

8 AZAGUANINE; AMINOPTERIN; HYPOXANTHINE; THYMIDINE;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DNA MICROARRAY; DRUG SENSITIVITY; EWING SARCOMA; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOID CELL LINE; PRIORITY JOURNAL; TUMOR CELL; X CHROMOSOME INACTIVATION;

AMINOPTERIN; ANTIGENS, NEOPLASM; AZAGUANINE; CALMODULIN-BINDING PROTEINS; CANCER VACCINES; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HLA-A2 ANTIGEN; HUMANS; HYPOXANTHINE; IMMUNOTHERAPY, ACTIVE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEINS; SARCOMA, EWING'S; THYMIDINE;

EID: 75149188673     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Staege MS and Max D: Genetics and epigenetics of the TET-ETS translocation network. Genetics and Epigenetics 2: 1-15, 2009.
2. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME and Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992, 2005.
3. Maksimenko A, Lambert G, Bertrand JR, Fattal E, Couvreur P and Malvy C: Therapeutic potentialities of EWS-FLI-I mRNA-targeted vectorized antisense oligonucleotides. Ann N Y Acad Sci 1002: 72-77, 2003.
4. Toub N, Bertrand JR, Tamaddon A, Elhamess H, Hillaireau H, Maksimenko A, Maccario J, Malvy C, Fattal E and Couvreur P: Efficacy of siRNA nanocapsules targeted against the EWS-FLI-I oncogene in Ewing sarcoma. Pharm Res 23: 892-900, 2006.
5. Hühn R, Staege MS, Hesse M, Liebig L and Burdach SEG: Cleavage of the Ewing tumour-specific EWSRl-FLI1 mRNA by hammerhead ribozymes. Anticancer Res 29: 1901-1908, 2009.
6. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ and Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38: 158-164, 2002.
7. Mackall C, Berzofsky J and Helman LJ: Targeting tumor-specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res 373: 25-31, 2000.
8. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA and Helman LJ: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14: 4850-4858, 2008.
9. Meyer-Wentrup F, Richter G and Burdach S: Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr Hematol Oncol 22: 297-308, 2005.
10. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D and Burdach SE: DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 64: 8213-8221, 2004.
11. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I and Staege MS: Membrane-associated phospholipase AI beta (LIPI) is a Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 51: 228-234, 2008.
12. Staege MS, Hansen G, Baersch G and Burdach S: Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer 43: 23-34, 2004.
13. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E and Lyerly HK: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235: 540-549, 2002
14. + progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Padiatr 216: 176-182, 2004.
15. Guo W, Guo Y, Tang S, Qu H and Zhao H: Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity. Clin Orthop Relat Res 466: 2176-2183, 2008.
16. Matsue H, Matsue K, Edelbaum D, Walters M, Morita A and Takashima A: New strategy for efficient selection of dendritic cell-tumor hybrids and clonal heterogeneity of resulting hybrids. Cancer Biol Ther 3: 1145-1151, 2004.
17. Van Snick J, Uyttenhove C, Van Pel A and Boon T: Stimulation of cytolytic T lymphocytes by azaguanine-resistant mouse tumor cells in selective HAT medium. J Immunol Methods 46: 321-326, 1981.
18. Migeon BR, Der Kaloustian VM, Nyhan, WL, Young WJ and Childs B: X-linked hypoxanthine-guanine phosphoribosyl transferase deficiency: heterozygote has two clonal populations. Science 160: 425-427, 1968.
19. Gordon S: Cell fusion and some subcellular properties of heterokaryons and hybrids. J Cell Biol 67: 257-280, 1975.
20. Biedler JL, Helson L and Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33: 2643-2652, 1973.
21. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
22. Salcedo M, Momburg F, Hämmerling GJ and Ljunggren HG: Resistance to natural killer cell lysis conferred by TAP 1/2 genes in human antigen-processing mutant cells. J Immunol 152: 1702-1708, 1994.
23. Foell JL, Volkmer I, Giersberg C, Kornhuber M, Horneff G and Staege MS: Loss of detectability of Charcot-Leyden crystal protein transcripts in blood cells after treatment with dimethyl sulfoxide. J Immunol Methods 339: 99-103, 2008.
24. + starting populations. J Hematother Stem Cell Res 12: 289-299, 2003.
25. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES and Golub TR: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442, 2002.
26. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T, Toyoda M, Katagiri YU, Fujimoto J, Hata J, Umezawa A and Kiyokawa N: Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 28: 2125-2137, 2008.
27. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P and Delattre O: Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429, 2007.
28. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA and Houghton PJ: Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14: 4572-4583, 2008.
29. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132, 2006.
30. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 1001.
31. Staege MS, Gisch K and Reske-Kunz AB: Cytotoxic T cells with reciprocal antigenic peptide presentation function are not generally resistant to mutual lysis. Immunol Cell Biol 81: 266-274, 2003.
32. Rammensee H, Bachmann J, Emmerich NP, Bachor OA and Stevanović S: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219, 1999.
33. Rodeberg DA, Nuss RA, Elsawa SF and Celis E: Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 11: 4545-4552, 2005.
34. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T and Coulie PG: Differences in the antigens recognized by cytolytic T-cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25: 340-347, 1995.
35. + T-cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 33: 556-566, 2003.
36. Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G and Vile RG: Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 65: 2009-2017, 2005.
37. Kim R, Emi M and Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14, 2007.
38. Wahl U, Nössner E, Kronenberger K, Gangnus R, Pohla H, Staege MS, Kolb HJ, Hallek M and Mocikat R: Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. Clin Cancer Res 9: 4240-4246, 2003.
39. Staege MS, Gorelov V, Bulankin A, Fischer U, Dumon K, Hohndorf L, Hattenhorst U, Kramm C and Burdach S: Stable transgenic expression of IL-2 and HSV1-tk by single and fusion tumor cell lines bearing EWS/FLI-1 chimeric genes. Pediatr Hematol Oncol 20: 119-140, 2003.
40. Panning B, Dausman J and Jaenisch R: X chromosome inactivation is mediated by XIST RNA stabilization. Cell 90: 907-916, 1997.
41. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, Mok SC, Berkowitz RS and Ng SW: Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther 1: 769-776, 2002.
42. Boukerche H, Su ZZ, Kang DC and Fisher PB: Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene 343: 191-201, 2004.
43. Kluiver J, Kok K, Pfeil I, de Jong D, Blokzijl T, Harms G, van der Vlies P, Diepstra A, Atayar C, Poppema S, Küppers R and van den Berg A: Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma. Hematol Oncol 25: 21-29, 2007.
44. Pilarsky C, Wenzig M, Specht T, Saeger HD and Grützmann R: Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6: 744-750, 2004.